# A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting

> **NCT07709897** · PHASE2 · RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Prevention of Postoperative Nausea and Vomiting

## Interventions

- **DRUG:** HRS5580 for injection combined with palonosetron hydrochloride;
- **DRUG:** HRS5580 for injection combined with palonosetron hydrochloride
- **DRUG:** HRS5580 for injection blank preparation combined with palonosetron hydrochloride

## Key facts

- **NCT ID:** NCT07709897
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-06
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709897, "A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07709897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*